Screening of tumor necrosis factor receptor-associated factor 6 as a candidate gene for inflammatory bowel disease

References

• Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124: 521–36
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521–33
   PubMed Web of Science ®Google Scholar
• Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 2003; 37: 358–67
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599–603
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et alBonen DK, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603–6
   PubMed Web of Science ®Google Scholar
• van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004; 13: 763–70
   PubMed Web of Science ®Google Scholar
• Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99: 2393–404
   PubMed Web of Science ®Google Scholar
• Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003; 52: 558–62
   PubMed Web of Science ®Google Scholar
• Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004; 41: 1099–108
   PubMed Web of Science ®Google Scholar
• Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 2000; 254: 14–24
   PubMed Web of Science ®Google Scholar
• Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001; 20: 6482–91
   PubMedGoogle Scholar
• Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115: 679–88
   PubMed Web of Science ®Google Scholar
• Ishida T, Mizushima S, Azuma S, Kobayashi N, Tojo T, Suzuki K, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996; 271: 28745–8
   PubMed Web of Science ®Google Scholar
• Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002; 418: 443–7
   PubMed Web of Science ®Google Scholar
• Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol 2004; 38: 218–24
   PubMedGoogle Scholar
• Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13: 1015–24
   PubMed Web of Science ®Google Scholar
• Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999; 4: 353–62
   PubMed Web of Science ®Google Scholar
• Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995; 332: 1475–80
   PubMed Web of Science ®Google Scholar
• Halme L, Turunen U, Helio T, Paavola P, Walle T, Miettinen A, et al. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol 2002; 37: 692–8
   PubMed Web of Science ®Google Scholar
• Helio T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003; 52: 558–62
   PubMed Web of Science ®Google Scholar
• Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996; 383: 443–6
   PubMed Web of Science ®Google Scholar
• Grech A, Quinn R, Srinivasan D, Badoux X, Brink R. Complete structural characterisation of the mammalian and Drosophila TRAF genes: implications for TRAF evolution and the role of RING finger splice variants. Mol Immunol 2000; 37: 721–34
   PubMedGoogle Scholar
• Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol 2005; 174: 1081–90
   PubMedGoogle Scholar
• Lomaga MA, Henderson JT, Elia AJ, Robertson J, Noyce RS, Yeh WC, et al. Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS. J Neurosci 2000; 20: 7384–93
   PubMedGoogle Scholar
• Bernstein CN, Leslie WD. Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 19: 941–52
   PubMed Web of Science ®Google Scholar
• Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031–9
   PubMed Web of Science ®Google Scholar
• Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111: 1263–71
   PubMedGoogle Scholar
• Qasim A, Seery J, Morain CA. Osteoporosis in newly diagnosed inflammatory bowel disease. Gastroenterology 2001; 121: 504–6
   PubMedGoogle Scholar
• Chu CS, Trapnell BC, Murtagh JJ, Jr, Moss J, Dalemans W, Jallat S, et al. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J 1991; 10: 1355–63
   PubMed Web of Science ®Google Scholar
• Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993; 3: 151–6
   PubMed Web of Science ®Google Scholar
• Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995; 332: 1475–80
   PubMed Web of Science ®Google Scholar
• Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002; 3: 248–54
   PubMed Web of Science ®Google Scholar
• Bream JH, Carrington M, O'Toole S, Dean M, Gerrard B, Shin HD, et al. Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics 2000; 51: 50–8
   PubMedGoogle Scholar